ZG005 + etoposide + cisplatin

ZG005 + etoposide + cisplatin is an **experimental combination therapy** currently being investigated for advanced neuroendocrine carcinoma. ZG005 is a biologic (specifically, a bispecific antibody targeting PD-1 and CTLA-4), combined with the chemotherapeutic agents etoposide and cisplatin. The mechanism of action for ZG005 involves immune checkpoint inhibition, enhancing anti-tumor immune responses. Etoposide is a topoisomerase II inhibitor, causing DNA damage and apoptosis in rapidly dividing cells, while cisplatin is a platinum-based DNA crosslinking agent, also leading to apoptosis of cancer cells. The combination of these agents is being evaluated in a phase 1/2 trial for safety, tolerability, and preliminary efficacy as first-line therapy for advanced neuroendocrine carcinoma[1][2][4][5][7].